Benitec Biopharma (BNTC) Income towards Parent Company (2019 - 2025)

Benitec Biopharma (BNTC) has 7 years of Income towards Parent Company data on file, last reported at -$28.2 million in Q4 2025.

• For the quarter ending Q4 2025, Income towards Parent Company rose 99.73% year-over-year to -$28.2 million; the trailing twelve-month figure through Dec 2025 stood at -$29.6 billion (down 64.51% YoY), and the FY2025 full-year result was -$7.8 billion, down 228.5% from the prior year.
• Income towards Parent Company improved to -$28.2 million in Q4 2025, from -$17.4 billion in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$3.6 million in Q1 2022 to a low of -$17.4 billion in Q3 2025.
• A 5-year average of -$2.4 billion and a median of -$13.3 million in 2023 frame the typical range for Income towards Parent Company.
• Across the five-year window, Income towards Parent Company plunged 78152.51% in 2024 and soared 99.73% in 2025, its largest moves.
• Tracing BNTC's Income towards Parent Company over 5 years: stood at -$5.0 million in 2021, then slipped by 27.07% to -$6.3 million in 2022, then plunged by 187.36% to -$18.2 million in 2023, then slumped by 57110.74% to -$10.4 billion in 2024, then soared by 99.73% to -$28.2 million in 2025.
• Business Quant data shows BNTC's Income towards Parent Company at -$28.2 million in Q4 2025, -$17.4 billion in Q3 2025, and -$10.2 million in Q2 2025.